Bristol-Myers Squibb BMY and Pfizer PFE
today announced the results of the six month Phase 3 AMPLIFY trial of
5,395 patients with acute venous thromboembolism (VTE), which includes
symptomatic deep vein thrombosis (DVT) and/or pulmonary embolism (PE).
In this trial, Eliquis as a single-agent achieved the primary efficacy
endpoint of noninferiority to current standard of care (initial
parenteral enoxaparin treatment overlapped with warfarin therapy) in the
reduction of the composite endpoint of recurrent symptomatic VTE or
VTE-related death.
Eliquis also met the primary safety endpoint of superiority for major
bleeding, with a 69 percent relative risk reduction (RRR) compared to
current standard of care.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in